DK0492105T3 - Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi - Google Patents

Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi

Info

Publication number
DK0492105T3
DK0492105T3 DK91119183.1T DK91119183T DK0492105T3 DK 0492105 T3 DK0492105 T3 DK 0492105T3 DK 91119183 T DK91119183 T DK 91119183T DK 0492105 T3 DK0492105 T3 DK 0492105T3
Authority
DK
Denmark
Prior art keywords
angiotensin
treatment
cardiac hypertrophy
receptor blocks
receptor
Prior art date
Application number
DK91119183.1T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Dr Linz
Holger Dr Heitsch
Hansjoerg Dr Urbach
Rainer Dr Henning
Bernward Prof Dr Schoelkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0492105T3 publication Critical patent/DK0492105T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Recrystallisation Techniques (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK91119183.1T 1990-11-17 1991-11-11 Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi DK0492105T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4036706A DE4036706A1 (de) 1990-11-17 1990-11-17 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (1)

Publication Number Publication Date
DK0492105T3 true DK0492105T3 (da) 1994-11-07

Family

ID=6418475

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91119183.1T DK0492105T3 (da) 1990-11-17 1991-11-11 Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi

Country Status (20)

Country Link
US (1) US5236943A (ko)
EP (1) EP0492105B1 (ko)
JP (1) JP3370347B2 (ko)
KR (1) KR100221686B1 (ko)
CN (1) CN1049116C (ko)
AT (1) ATE108656T1 (ko)
AU (1) AU652590B2 (ko)
BR (1) BR9104918A (ko)
CA (1) CA2055637C (ko)
CZ (1) CZ283236B6 (ko)
DE (2) DE4036706A1 (ko)
DK (1) DK0492105T3 (ko)
ES (1) ES2060274T3 (ko)
HR (1) HRP940765B1 (ko)
HU (1) HU219404B (ko)
IE (1) IE66461B1 (ko)
MX (1) MX9102100A (ko)
NO (1) NO914482L (ko)
SK (1) SK280304B6 (ko)
ZA (1) ZA919056B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5935990A (en) * 1996-12-10 1999-08-10 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
ES2154191B1 (es) * 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EP1427408A4 (en) * 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
ITTO20040264A1 (it) * 2004-04-28 2004-07-28 Rotta Res Lab Spa Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
CA2575177A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Purification of olmesartan medoxomil
CN1993355A (zh) * 2004-09-02 2007-07-04 特瓦制药工业有限公司 奥美沙坦酯的纯化方法
US20060258727A1 (en) * 2005-01-03 2006-11-16 Lilach Hedvati Olmesartan medoxomil with reduced levels of impurities
BRPI0814542A2 (pt) 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
RU2500668C2 (ru) 2008-08-15 2013-12-10 Н30 Фармасьютиклз, ИНК. Новые пиррольные ингибиторы s-нитрозоглутатионредуктазы в качестве терапевтических агентов
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
US8642628B2 (en) * 2008-08-15 2014-02-04 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase
CN102816126A (zh) * 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488084A (en) * 1892-12-13 Blank-feeding device
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
DE4036645A1 (de) * 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung

Also Published As

Publication number Publication date
US5236943A (en) 1993-08-17
SK280304B6 (sk) 1999-11-08
HU219404B (hu) 2001-04-28
CN1049116C (zh) 2000-02-09
AU8785891A (en) 1992-05-21
NO914482D0 (no) 1991-11-15
CN1062289A (zh) 1992-07-01
ATE108656T1 (de) 1994-08-15
ES2060274T3 (es) 1994-11-16
BR9104918A (pt) 1992-06-23
JP3370347B2 (ja) 2003-01-27
HUT59599A (en) 1992-06-29
CS347191A3 (en) 1992-06-17
ZA919056B (en) 1992-07-29
HRP940765B1 (en) 2000-08-31
CZ283236B6 (cs) 1998-02-18
IE913992A1 (en) 1992-05-20
EP0492105A2 (de) 1992-07-01
CA2055637A1 (en) 1992-05-18
KR100221686B1 (ko) 1999-09-15
DE4036706A1 (de) 1992-05-21
MX9102100A (es) 1992-07-08
JPH04290823A (ja) 1992-10-15
EP0492105A3 (en) 1992-07-29
AU652590B2 (en) 1994-09-01
IE66461B1 (en) 1995-12-27
KR920009393A (ko) 1992-06-25
CA2055637C (en) 2003-11-11
NO914482L (no) 1992-05-18
HRP940765A2 (en) 1997-08-31
EP0492105B1 (de) 1994-07-20
HU913581D0 (en) 1992-01-28
DE59102259D1 (de) 1994-08-25

Similar Documents

Publication Publication Date Title
DK0492105T3 (da) Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi
MY104140A (en) Substituted pyrrole, pyrazole and triazole angiotensin ii antagonists
DE69816109D1 (de) Substituierte imidazole zur behandlung von entzündlichen krankheiten
DE69322254D1 (de) Pyridyl-substituierte imidazole
NO176049C (no) Analogifremgangsmåte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-II-reseptorer
BR9606904A (pt) Alguns compostos imidazol 1,4,5-tri-substituídos utilizáveis como citocina
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
IS4975A (is) Aðferð til meðhöndlunar á hjartabilun
DK600788D0 (da) Triazol- eller imidazolforbindelser, fremgangsmaade til fremstilling deraf og anvendelse af saadanne forbindelser som fungicider
IS3985A (is) Aðferð við framleiðslu á 1,2,3,9-tetrahýdró-9-metýl-3-[(2-metýl-1H-imídazól-1-ýl)metýl]-4H-karbasól-4-ón
DK0959878T3 (da) Fremgangsmåde til behandling af nyresvigt